PRE-CONFERENCE
WORKSHOP - MONDAY 4 October 2004 |
|
 |
|
|
Workshop 14.00-17.00 |
BIOEXEC
Ventures, LLC presents Connecting with the US: Strategies and Lessons for Establishing a Presence in the US Market Click here to see full details |
|
|
Agenda |
DAY
ONE - Tuesday 5 October 2004 |
|
|
08.30 |
|
|
|
Session
1 08.40 |
Keynote:
Exploring the linkage
between the US and European Markets Dennis Purcell, Senior Managing Director, Perseus-Soros BioPharmaceutical Fund |
|
|
Session
2 09.00 |
Investment
Themes for 2005 Chair: Hoda Abou-Jamra, Founder & CEO, BioExec Ventures LLC Discussants: Joël Besse, Senior Partner, Atlas Venture Denise Pollard-Knight, Head of Nomura Phase·4 Ventures, Nomura International plc Dr Alexandra Goll, General Partner, Techno Venture Management GmbH (TVM) |
|
|
Session
3 09.55 |
Corporate Funding
through Capital Markets Discussants: Dr. rer. nat. Markus Metzger, Senior Analyst Biotech, Bank Vontobel AG Marc Zahn, Vice President, Head of Marketing and Sales, SWX Swiss Exchange |
|
|
10.35 |
BREAK |
|
|
Session
4 11.05 |
Company
Presentations: Listed Companies
|
|
|
13.10 |
LUNCH |
|
|
Session
5 14.15 |
Company
Presentations in Workshops Venture Funded Early to Mid Stage Biotechs • Therapeutics • Immunology/Oncology • Post-Genomics • MedTech |
|
|
15.45 |
BREAK |
|
|
Session
6 16.15 |
Exploring
the Attractiveness of the Life Science Sector to Investors Dr. Peter Reinisch, Partner, Global Life Science Ventures |
|
|
Session
7 16.40 |
LP Fund of Funds Advisors Panel: Asset
Allocation into Life Sciences Chair: Dr Katerina Lichtner, Founding Partner, Capital Dynamics Discussants: Susan Flynn, Partner, Coller Capital Otello Stampacchia, Founder, Omega Investors Hans van Swaay, Head of Private Equity, Pictet & Cie William van Eesteren, Director, Wilshire Associates Europe |
|
|
Session
8 17.20 |
Global Investor Roundtable Chair: Stan Yakatan, Chairman, Katan Associates Discussants: Dr Brian Hargreaves, Global Sector Head – Healthcare, 3i Group plc Marc Perret, Director, Gilde Investment Management Dr Andreas Wicki, CEO, HBM Partners Adi Seffer, Partner, Morgan Lewis Antoine Papiernik, Managing Partner, Sofinnova Nick Lowcock, Managing Director, Warburg Pincus |
|
|
18.30 |
COCKTAIL
RECEPTION |
|
|
| Agenda |
DAY TWO - Wednesday 6 October 2004 |
|
|
08.45 |
|
|
|
Session
9 09.00 |
Keynote: M&A Martin Friedman, Global Head Pharma M&A and Collaborations, Global Business Development and Licensing, Novartis Pharmaceuticals Corporation |
|
|
Session
10 09.20 |
Bio Partnering
Current Trends in ‘In and Out’ Licensing of Big Pharmas Chair: Anthony Warnock-Smith, Partner, Morgan Lewis Discussants: Dr. Chris Henderson, Director Global Licensing, AstraZeneca Dr. Jonathan D Turner, Head of Corporate Dept. Pharmaceutical Licensing, Boehringer Ingelheim Jonathan Freeman, Director, Strategy & Portfolio Evaluation Corporate Business Development, Serono International |
|
|
10.05 |
BREAK |
|
|
Session
11 10.25 |
Company Presentations in Workshops: Venture Funded Early to Mid Stage Biotechs • Therapeutics • Immunology/Oncology |
|
|
12.25 |
LUNCH |
|
|
Session
12 13.30 |
Deal Making as
a Unique Financing Tool Chair: Dimitri F Dimitriou, Chief Executive Officer, DyoDelta Biosciences Ltd Discussants: Tim McCarthy, CFO, Alizyme Spiro Rombotis, CEO, Cyclacel Sandrine Cailleteau, Head of Corporate Business Development & Licensing, Laboratories Fournier S.A. Dr Andrew Barber, Global Licensing & Business Development Leader, Corporate Business Development, Merck KGaA Dr Frank Grams, Global Alliance Director, Roche |
|
|
|
Session
13 14.45 |
Company Presentations in Workshops: Venture Funded Early to Mid Stage Biotechs • Therapeutics • Immunology/Oncology |
16.15 |
END
OF CONFERENCE |